NEW YORK, June 7 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
The pharmaceutical industry is challenged with information integration and mapping across the various business processes. This information challenge, along with other issues such as weak product development pipelines, growing generics competition, and rising R&D and regulatory compliance costs are compelling pharmaceutical companies to look for alternatives to remain competitive, maintain profit margins, and enhance market share. Implementation of Business Intelligence (BI) enables the business processes to access more accurate and real-time information, with an ultimate goal of increased efficiency and reduced corporate costs.
This report provides an overview of the BI market in the pharmaceutical sector, including its size and growth, followed by the current trends of BI technologies and adoption of BI tools across key pharmaceutical processes. It gives an insight into the various key players in the BI market, analyzing them based on their product offerings and growth strategies. In addition to the BI supply side, this report assesses the state of the BI market from the demand side perspective. Demand side analysis investigates the uptake of BI in the pharmaceutical sector, investments in current BI use, and planned future use.
Key features of this report
- Analysis of the BI market in the pharmaceutical sector in terms of size and growth rate.
- Evaluation of the drivers behind the increased spending on BI solutions by Big Pharma companies.
- Key challenges in developing a data warehouse that delivers BI capabilities for the pharmaceutical industry.
- Demand side analysis of the uptake of BI in the pharmaceutical sector, investment in current BI use, and planned future use.
- Insight into the activities, views, and strategies of the major BI vendors.
Scope of this report
- Understand the BI needs across major pharmaceutical industry processes and the benefits that entail from BI implementation.
- Understand the uptake of BI in the pharmaceutical sector by organization size and by geographic location.
- Identify the organizational priorities of life science companies and how BI can improve the quality of decision making.
- Benchmark your performance against the major BI vendors based on knowledge of their product offerings and growth strategies.
Key Market Issues
- The data intensive nature of the pharmaceutical industry makes BI deployment more challenging than other industries.
- Data availability at different time periods, frequent changes in the legislation, and growing consolidation in the pharmaceutical industry makes the BI adoption process particularly challenging.
- Reduction of knowledge process service costs is a pressing priority for most pharmaceutical companies.
- BI vendors need to work with the pharmaceutical companies to identify areas or patterns where the costs can be reduced and educate the pharmaceutical companies about the advantages of moving towards adopting easy to use and prepackaged pharma-specific BI solutions.
Key findings from this report
- The BI market in the pharmaceutical industry was worth around $495m in 2009, and is forecast to grow to $555m by 2012.
- Besides achieving operational excellence, pharmaceutical companies are investing in BI implementation in technical areas, such as to improving research and clinical performance, resource management, sales force tracking and regulatory compliance reporting.
- Business Insights' survey of the pharmaceutical sector found that 67% of the respondents currently use BI tools.
- Of current users, 71% have indicated that launching new products and services in existing markets is likely to influence their decision over whether to increasingly use BI tools and services in 2010–11.
- Approximately 49% of respondents confirmed their intention to reduce SG&A costs in 2010–11.
Key questions answered
- What is the market size and growth rate over the period 2006-2012 for BI spending in pharmaceutical sector?
- What are the major drivers for increased BI adoption in the pharmaceutical sector?
- What are the key challenges that make BI adoption difficult for the industry?
- What does the current BI vendor landscape look like?
- How will the emerging advanced analytics capabilities and industry/process-specific offerings determine which vendors remain dominant in the future?
Table of Contents
Business Intelligence in the Pharmaceutical Market
Executive summary 10
The Business Intelligence market in the pharmaceutical sector 10
Key processes in the pharmaceutical sector 10
The uptake of Business Intelligence in the pharmaceutical sector 11
The demand side of Business Intelligence in the pharmaceutical sector 12
The Business Intelligence vendor landscape 12
The future of the Business Intelligence market in the pharmaceutical sector 13
Chapter 1 Introduction 16
Who is this report for? 17
Research methodology 17
Chapter 2 The Business Intelligence market in the pharmaceutical sector 20
Importance of BI in the pharmaceutical industry 21
BI market in the pharmaceutical industry: size and growth 22
Drivers for BI adoption in the pharmaceutical industry 24
Enabling strategic decision making 25
Enabling identification of latest sales forecasts and trends 25
Increased outsourcing 26
Attaining cost efficiency 26
Challenges for implementing BI in the pharmaceutical industry 26
Current BI trends in the pharmaceutical industry 27
BI moving beyond operational excellence to technical areas 29
Customized service offering by BI vendors 29
Chapter 3 Key processes in the pharmaceutical sector 32
Pharmaceutical processes 33
Drug discovery 34
Drug development 34
Manufacturing and supply chain 35
Sales and marketing 36
Chapter 4 The uptake of Business Intelligence in the pharmaceutical sector 40
Business Intelligence uptake 41
Current BI usage 41
Uptake by organization size 42
Uptake by geographies 43
Short-term BI drivers among current users 44
Longer-term BI drivers among current users 45
BI usage forecast 46
BI usage forecast by components 47
BI usage forecast by enterprise functions 47
Planned increases in spending on Business Intelligence 48
Plans to increase usage: case for persuasion 50
Chapter 5 The demand side of Business Intelligence in the pharmaceutical sector 52
Organizational priorities 52
Cost reduction: which areas to target? 54
Reducing SG&A costs 54
Cost reduction priorities 55
Business Intelligence users – case studies 56
GlaxoSmithKline – management of the clinical trial process and enhancement of drug development 57
Wyeth Pharma – managing sales effectiveness 57
Chapter 6 The Business Intelligence vendor landscape 60
The mega vendors 62
IBM Business Intelligence: Cognos, SPSS, ILOG, and IBM BAO 63
Company overview 63
Key offerings and verticals 63
Pharmaceutical solutions and major customers 64
Growth strategies 65
Microsoft Business Intelligence 66
Company overview 66
Key offerings and verticals 67
Pharmaceutical solutions and major customers 68
Growth strategies 69
Company overview 70
Key offerings and verticals 70
Pharmaceutical solutions and major customers 71
Growth strategies 72
SAP BusinessObjects 73
Company overview 73
Key offerings and verticals 73
Pharmaceutical solutions and major customers 75
Growth strategies 76
Niche vendors 77
Company overview 77
Key offerings and verticals 78
Pharmaceutical solutions and major customers 78
Growth strategies 79
Information Builders 80
Company overview 80
Key offerings and verticals 80
Pharmaceutical solutions and major customers 81
Growth strategies 82
Company overview 82
Key offerings and verticals 83
Pharmaceutical solutions and major customers 84
Growth strategies 85
Company overview 86
Key offerings and verticals 86
Pharmaceutical solution and major customers 86
Growth strategies 87
Company overview 88
Key offerings and verticals 88
Pharmaceutical solutions and major customers 89
Growth strategies 90
TIBCO Spotfire 91
Company overview 91
Key offerings and verticals 91
Pharmaceutical solutions and major customers 92
Growth strategies 93
Chapter 7 The future of the Business Intelligence market in the pharmaceutical sector 96
Transition of the pharmaceutical sales and marketing model through predictive analytics 98
Major vendors 99
Shifting to in-memory analytics helps rapid information delivery to the sales force 100
Major vendors 100
Leveraging SaaS for data analytics 101
Major vendors 101
Open source paving its way into SMBs 102
Major vendors 102
List of Figures
Figure 2.1: BI spending by big pharma in the US and Europe ($m), 2006–2012 23
Figure 2.2: Drivers and challenges for BI implementation in the pharmaceutical industry 24
Figure 2.3: Current BI trends in the pharmaceutical industry 28
Figure 3.4: Pharma-specific typical Business Intelligence solutions 33
Figure 4.5: BI usage by organizations (% respondents, 2010) 41
Figure 4.6: Current BI users by areas of operation (% respondents using BI, 2010) 42
Figure 4.7: BI users by organization size (% respondents, 2010) 43
Figure 4.8: BI users by geography (% respondents, 2010) 44
Figure 4.9: Short-term factors most likely to drive BI uptake among current users 45
Figure 4.10: Longer-term factors likely to drive BI uptake among current users (% respondents) 46
Figure 4.11: Forecast of BI usage by components (% respondents) 47
Figure 4.12: Forecast of BI usage by enterprise functions (% respondents) 48
Figure 4.13: Current user plans to change spending on BI in 2010–2011 49
Figure 4.14: Case for persuasion: current BI user indecisiveness by enterprise functions 50
Figure 5.15: Organizational priorities 53
Figure 5.16: Is reduction of SG&A costs a high priority in 2010? 55
Figure 5.17: Cost reduction priorities by enterprise function 56
Figure 6.18: Business Intelligence vendor landscape 61
Figure 6.19: Summary of the mega vendors 62
Figure 7.20: Spectrum of Business Intelligence technologies 97
List of Tables
Table 3.1: Drug discovery KPIs and BI solutions 34
Table 3.2: Drug development KPIs and BI solutions 35
Table 3.3: Manufacturing and supply chain KPIs and BI solutions 36
Table 3.4: Sales and marketing KPIs and BI solutions 37
Table 6.5: IBM Cognos Business Intelligence offerings 63
Table 6.6: IBM Cognos pharmaceutical solutions 65
Table 6.7: IBM major M&A deals, 2008–2010* 66
Table 6.8: Microsoft Business Intelligence offerings 67
Table 6.9: Microsoft Business Intelligence pharmaceutical solutions 68
Table 6.10: Microsoft Business Intelligence major M&A deals, 2008–2010* 70
Table 6.11: Oracle Business Intelligence offerings 71
Table 6.12: Oracle pharmaceutical solutions 71
Table 6.13: Oracle major M&A deals, 2008–10* 73
Table 6.14: SAP BusinessObjects Business Intelligence offerings 74
Table 6.15: SAP BusinessObjects pharmaceutical solutions 75
Table 6.16: SAP BusinessObjects major M&A deals, 2008–2010* 77
Table 6.17: Actuate Business Intelligence offerings 78
Table 6.18: Actuate pharmaceutical solutions 79
Table 6.19: Actuate major M&A deal, 2008–2010* 80
Table 6.20: Information Builders' Business Intelligence offerings 81
Table 6.21: Information Builders' pharmaceutical solutions 81
Table 6.22: MicroStrategy Business Intelligence offerings 83
Table 6.23: MicroStrategy pharmaceutical solutions 84
Table 6.24: QlikTech pharmaceutical solutions 87
Table 6.25: SAS Business Intelligence offerings 88
Table 6.26: SAS pharmaceutical solutions 89
Table 6.27: SAS major M&A deals, 2008–2010* 91
Table 6.28: TIBCO Spotfire Business Intelligence offerings 92
Table 6.29: TIBCO Spotfire pharmaceutical solutions 92
Table 6.30: TIBCO Spotfire major M&A deal, 2008–2010* 94
To order this report:
Intl: +1 805-652-2626